Multiplex Biomarker Imaging Market to Experience Double-Digit Revenue Growth During 2019-2029
The need to facilitate patients with enhanced diagnosis and treatment of tumors at a cellular level is accenting the demand for advanced diagnostic imaging services such as multiplex biomarker imaging. Moreover, governments all over the world are providing financial support to medical institutes and research centers for immuno-oncology research. Growing at a robust CAGR of 12%, the worldwide adoption of multiplex biomarker imaging technique is expected to be valued at US$ 335 Mn in 2019, and triple over the next decade.
Frequently Asked Questions about Multiplex Biomarker Imaging Market
What is the current and future market status of multiplex biomarker imaging?
The global multiplex biomarker imaging market is anticipated to experience robust growth in the foreseeable future, and is expected to expand nearly 3X its current market value by the end of 2029.
Which trend is prominent that favors the growth of the multiplex biomarker imaging market?
Over the last few years, there has been greater demand for advanced methods for offering functional evidence on cellular protein components of cancerous tissues. Additionally, tech developments for better diagnosis and management of various oncological disorders are anticipated to bolster the demand for multiplex biomarker imaging techniques.
Where does major opportunity lie?
Demand is primarily emerging from developing countries such as China and India for cancer research, especially non-small cell lung cancer (NSCLC), for improved stratification of patients and faster diagnosis. Better accessibility to advanced healthcare and diagnostic infrastructure, as well as the establishment of translational laboratories are factors contributing to the growing number of multiplex biomarker imaging methods.
Which players are identified as tier-1 players in the multiplex biomarker imaging market?
PerkinElmer, Bio-Rad, and Thermo Fisher Scientific are some of key players in the multiplex biomarker imaging market that FMI has recognized as tier-1 players. Most of these players are focusing on expansion through strategic acquisition of regional players to maintain their market position in the multiplex biomarker imaging market.
Which end-use industry offers high potential opportunities for market players?
Translational laboratories are anticipated to represent a significant market share in the multiplex biomarker imaging market, and remain the most lucrative segment throughout the forecast period, as they deliver high-quality R&D services involving cancer biomarkers.
Instruments to Account for Higher Market Share
By capturing nearly 3/4 share of total market value, instruments continue to lead the pack, with their share exhibiting an increasing trend through 2029. Under the component type, immunofluorescence slide scanners will remain highly preferred over other instruments such as multispectral imaging systems and toponome imaging systems. Benefits such as high image quality, reliability, and speed for entire slide imaging are influencing the inclination of manufacturers towards these instrument. Further, quantitative pathology imaging systems, although in their nascent stage, are also echoing potential sales prospects for market players.
Focus Sustained on Developed Regional Markets
Accounting for a collective share of 80%, North America and Western Europe will remain the key contributors to the revenue of the global multiplex biomarker imaging market. These developed regions continue to reflect lucrative growth potential due to supportive government policies and increasing financial assistance for laboratory and clinical research. Being early adopters of innovative technologies and advanced healthcare infrastructure, market players are dedicating a significant slice of their investments to these regions. Given the emergence of cutting-edge technologies and rising per capita healthcare spending in Asia Pacific (APAC), the multiplex biomarker imaging market in this region is also receiving an impetus.
* This data is only a representation. Actual data may vary and will be available in report.
Coupling Multispectral Imaging with Multiplexing for Broadened Application Scope
Multispectral imaging is gaining good reputation within the biomedical sphere, as it optimizes the multiplexing process and curbs the side effects of auto-fluorescence in sync. This could further serve several purposes, including identifying target protein expression, detection of exact tumor location, oxy-deoxy hemoglobin status, and documentation of drug delivery. Leading market players are leveraging this imaging technique by increasing the component ion base of multispectral imaging devices that could provide multiplexing biomarker imaging, which, in turn, would help reap bigger margins.
High demand for instruments
Increasing usage of software
IHC assays remain sought-after
FISH assays to gain rapid traction
Surging application in research
Adoption in clinical diagnostics on rise
Translational laboratories to remain key end users
Robust adoption in academic institutes
How Growth will Unfold
Considering efficiency in terms of processing time and accuracy during identification of target proteins in tissue samples, immunohistochemistry (IHC) assays will continue to stay at the forefront throughout the forecast period. This study reveals that, the adoption of this imaging technique will achieve its peak in 2022, registering revenue worth US$ 300 Mn. While IHC assay remain the focus of various immuno-oncology research, fluorescence in situ hybridization (FISH) and transcription-mediated amplification (TMA) assays are also finding immense utilization in molecular diagnostics applications.
* This data is only a representation. Actual data may vary and will be available in report.Click Here To Know How The Growth Will Unfold
Custom Market Research Services
FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.
Multiplex Biomarker Imaging Market Analysis 2019 - 2029
A recent market study published by Future Market Insights (FMI) on the multiplex biomarker imaging market includes global industry analysis for 2014-2018 and opportunity assessment for 2019-2029, and delivers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical as well as current growth parameters of the multiplex biomarker imaging market, the growth prospects of the market are obtained with maximum precision.
Multiplex Biomarker Imaging Market Taxonomy
The global multiplex biomarker imaging market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to readers.
- Quantitative Pathology Imaging Systems
- Immunofluorescence Slide Scanners
- Toponome Imaging Systems
- Multispectral Imaging Systems
- Installation & Integration Services
- Maintenance Services
- Immunohistochemistry (IHC) Assays
- Fluorescent In-Situ Hybridization (FISH) Assays
- Tissue Microarray (TMA) Assays
- Clinical Diagnostics
- Translation Laboratories
- Biopharmaceutical Companies
- Academic Institutes
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific Excluding Japan (APEJ)
- Middle East and Africa
The report initiates with the executive summary of the multiplex biomarker imaging market, which includes a summary of key findings and statistics of the market. It also includes demand & supply-side trends pertaining to the multiplex biomarker imaging market.
Readers can find the definition and a detailed segmentation of the multiplex biomarker imaging in this chapter, which will help them understand the basic information about the multiplex biomarker imaging market.
This chapter explains the key macroeconomic factors, drivers, restraints, trends, and opportunity analysis that are expected to influence the growth of the multiplex biomarker imaging market over the forecast period. Moreover, in-depth information about the market dynamics and their impact analysis on the market have been provided in the successive section.
This section includes the premium insights such as regulatory scenario, disease epidemiology, and parent market analysis. This section helps readers understand the key factors associated with the multiplex biomarker imaging market.
This section explains the global market value analysis and forecast for the multiplex biomarker imaging market during the forecast period of 2019-2029. This chapter includes a detailed analysis of the historical multiplex biomarker imaging market, along with an opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2019), and an incremental $ opportunity for the forecast period (2019–2029).
Based on component type, the multiplex biomarker imaging market is segmented into instruments, software, and services. In this chapter, readers can find information about the key trends and developments in the multiplex biomarker imaging market and attractiveness analysis based on component type.
This chapter provides details about the multiplex biomarker imaging market based on imaging technique, and has been classified as Immunohistochemistry (IHC) Assay, Fluorescent In-Situ Hybridization (FISH) Assay, and Tissue Microarray (TMA) Assay. In this chapter, readers can understand the market attractiveness analysis based on imaging technique.
This chapter provides details about the multiplex biomarker imaging market based on application, and has been classified into research and clinic diagnostics. In this chapter, readers can understand the market attractiveness analysis based on application.
This chapter provides details about the multiplex biomarker imaging market based on end user, and has been classified into translation laboratories, biopharmaceutical companies and academic. In this chapter, readers can understand the market attractiveness analysis based on end user.
This chapter explains how the multiplex biomarker imaging market will grow across various geographic regions such as North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, and Middle East & Africa (MEA).
This chapter includes a detailed analysis of the growth of the North America multiplex biomarker imaging market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the pricing analysis, regional trends, and market growth based on the application and countries in North America.
This chapter provides the growth scenario of the multiplex biomarker imaging market in Latin American countries such as Brazil, Mexico, Argentina and the Rest of Latin America. Along with this, assessment of the market across target segments has been provided.
Important growth prospects of the multiplex biomarker imaging market based on its end users in several countries such as Germany, the U.K., France, Spain, Italy, Russia, BENELUX, and the Rest of Europe are included in this chapter.
In this chapter, Russia, Poland & Rest of Eastern Europe countries are the prominent countries in the Eastern Europe region that are the prime subjects of assessment to obtain the growth prospects of the Eastern Europe multiplex biomarker imaging market. Readers can find detailed information about the growth parameters of the Eastern Europe multiplex biomarker imaging market during the forecast period of 2019-2029.
This chapter highlights the growth of the multiplex biomarker imaging in Asia Pacific excluding Japan by focusing on China, India, Australia & New Zealand, ASEAN and rest of APEJ. This section also help readers understand the key factors that are responsible for the growth of the multiplex biomarker imaging market in the APEJ region.
This chapter highlights the growth of the multiplex biomarker imaging market in Japan. This section also help readers understand the key factors that are responsible for the growth of the multiplex biomarker imaging market in Japan.
This chapter provides information about how the multiplex biomarker imaging market will grow in major countries in the MEA region such as GCC Countries, South Africa and the Rest of MEA, during the forecast period of 2019-2029.
In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the multiplex biomarker imaging market, along with a detailed information about each company, which includes company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are PerkinElmer Inc, Thermo Fisher Scientific, Inc., Abcam plc.
This chapter includes a list of acronyms and assumptions that provides a base to the information and statistics included in the multiplex biomarker imaging report.
This chapter help readers understand the research methodology followed to obtain various conclusions as well as important qualitative and quantitative information about the multiplex biomarker imaging market.
How the research was conducted?
- C - Level Executives
- Marketing Directors
- Product Managers
- Business Development Officers
- Production Managers
- Sales Executives
- Industry Experts
- Current Market Dynamics and Challenges
- Yesteryear Trends
- Market Characteristics
- Market Performance and Growth Quadrants
- Strategic Growth Initiatives
- Near-term and long-Term Market Growth Prospects
- Market Segment Splits and Authenticity
- Opinions on Market Projections and Validity of Assumptions
- Company Press Releases
- Annual Reports and Investor Presentations
- Research Papers
- Government Websites and Publications
Primary Interview Splits